A short review on antibody therapy for COVID-19
Govindarajan Venkat Kumar, V. Jeyanthi, Srividya Ramakrishnan
Abstract
The beginning of the novel SARS-CoV-2 human coronavirus in Wuhan, China, has triggered a worldwide respiratory disease outbreak (COVID-19). By April 07, 2020, SARS-CoV-2 has affected more than 1.36 million people worldwide and caused more than 75,900 deaths. To date, the anti-malaria drug hydroxychloroquine found to be a treatment option for SARS-CoV-2. In addition to supportive treatment, such as oxygen supply in moderate cases and extracorporeal membrane oxygenation in critically ill patients, unique medications for this condition are also under investigation. Here we reviewed the antibody therapy might be an immediate strategy for emergency prophylaxis and SARS-CoV-2 therapy.
Topics & Concepts
HydroxychloroquineMedicineCoronavirus disease 2019 (COVID-19)Extracorporeal membrane oxygenationOutbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Intensive care medicineOxygen therapyCoronavirus2019-20 coronavirus outbreakDiseasePandemicAntibodyVirologyImmunologyInfectious disease (medical specialty)Internal medicineSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19